CWRUObserver.com -Financial News and Headlines - NYSE, Nasdaq, OTC's

[sublime]

LIPD 1.30 Patient Enrollment in HDL Therapy Clinical Trial Approaches Completion
FDA Approves Expansion of Clinical Trial Sites; HDL Selective Delipidation Clinical Trial Featured in "Healthy Body, Healthy Mind" TV Series
Jul 30, 2007 8:30:00 AM

PLEASANTON, CA -- (MARKET WIRE) -- 07/30/07 -- Lipid Sciences, Inc. (NASDAQ: LIPD) today reported that enrollment is complete for two-thirds, or 20 out of a total target of 30 patients, in the Company's safety and feasibility clinical trial of HDL Selective Delipidation at the Washington Hospital Center in Washington, D.C.

Dr. S. Lewis Meyer, President and Chief Executive Officer noted, "The HDL Selective Delipidation procedures continue to be well tolerated by all patients. On a related matter, we have received approval from the FDA to add three additional hospital sites for this clinical trial in the Washington, D.C. area. With this approval, we will be able to increase the pool of eligible participants and move closer to our critical goal of completing this clinical trial by year end."

Lipid Sciences was featured on the public television series "Healthy Body, Healthy Mind." The segment entitled, "Cholesterol: Raising the Good and Lowering the Bad," addresses HDL as the next, most logical target for the development of treatments to combat cardiovascular disease. It highlights HDL therapy as having the potential to address a seriously unmet clinical need. Our HDL Selective Delipidation process was demonstrated in a clinical trial setting along with an interview of our first clinical trial participant. Dr. H. Bryan Brewer, Lipid Sciences' Chief Scientific Director, and Dr. Philip Barter, a member of our Scientific Advisory Board, both lipid metabolism experts, were interviewed about the importance of increasing the level of HDL or 'good cholesterol' as part of a cardiovascular treatment regimen. Dr. Brewer cautions the viewer that not properly managing HDL levels can lead to vulnerable plaque rupture and a major coronary event. Dr. Barter's comments recognize that for many years the focus of cardiovascular disease treatment has been on the lowering of the patient's LDL and, with that having been accomplished, it is now time to look seriously toward HDL therapy to make the treatment of cardiovascular disease that much more successful.

The program can be viewed in its entirety at www.itvisus.com/programs/hbhm/episode_802cholesterol.asp.

Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company's HDL Therapy platform (HDL Selective Delipidation and HDL Mimetic Peptides) aims to develop treatments to reverse atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy platform focuses on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by applying Lipid Sciences' proprietary delipidation technologies. The Company believes that removing the virus' protective lipid coating enhances the processing and presentation of viral proteins to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by these technologies include HIV, Hepatitis B and Hepatitis C, West Nile, SARS, influenza, and a broad range of animal health applications.

Forward-Looking Statements: This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers should refer to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds; the significant losses we have incurred to date, and our expectation that we will incur substantial losses in the future; the failure of our technologies to prove safe or effective; our inability to obtain regulatory approval for our technologies, which are only in the clinical development stage; delay or failure to complete clinical trials; our inability to add additional clinical trial sites; our dependence on our license agreement with Aruba International B.V.; our reliance on collaborations with strategic partners and consultants; competition in our industry, including the development of new products by others that may provide alternative or better therapies; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; acceptance of our potential products by healthcare providers and patients; our exposure to product liability claims; and our dependence on key personnel.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov. Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.

Press releases for Lipid Sciences, Inc. are available on our website: www.lipidsciences.com. If you would like to receive our press releases via email, please contact: [e-mail].

FOR FURTHER INFORMATION CONTACT:
Deborah S. Lorenz
Vice President, Investor Relations and Corporate Communications
Lipid Sciences, Inc.
925-249-4031
Email Contact